Showing results (6271-6280 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|October 27, 2005
Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosisA de Bartolomeis, G Fiore, F IasevoliCurrent Pharmaceutical Design|October 28, 2005
PET imaging in clinical drug abuse researchS John Gatley, Nora D Volkow, Gene-Jack Wang, et al.Current Pharmaceutical Design|October 28, 2005
Fluorine-18-labelled fluoropyridines: advances in radiopharmaceutical designF DolléCurrent Pharmaceutical Design|October 28, 2005
The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotectionLaurent Magy, François Vincent, Sebastien Faure, et al.Current Pharmaceutical Design|October 28, 2005
Vasopeptidase inhibition for blood pressure control: emerging experienceThomas QuaschningCurrent Pharmaceutical Design|April 12, 2002
Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonistsW Danysz, C G Parsons, A Jirgensons, et al.Current Pharmaceutical Design|April 12, 2002
NR2B selective NMDA receptor antagonistsSham S Nikam, Leonard T MeltzerCurrent Pharmaceutical Design|April 12, 2002
Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis CAntonio Ascione, Massimo De Luca, Giovan Giuseppe Di Costanzo, et al.Current Pharmaceutical Design|April 12, 2002
Main characteristics of hepatocellular carcinoma and cirrhosis and therapeutic approachesS Elba, G P Buongiorno, M L Caruso, et al.Current Pharmaceutical Design|April 12, 2002
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trialF Perrone, C Gallo, B Daniele, et al.Pageof 1,008